Current Concepts in Revascularization for Ischemic Heart Disease With Reduced Ejection Fraction.

Area of Science:

• Cardiology
• Heart Failure Research
• Interventional Cardiology

Background:

• Ischemic heart disease is a primary cause of heart failure with reduced ejection fraction.
• Medical therapy has improved outcomes for ischemic cardiomyopathy, but revascularization's role is debated.
• Prior trials like STICH and REVIVED-BCIS2 provide complex insights into revascularization benefits.

Purpose of the Study:

• To review current data on revascularization in ischemic cardiomyopathy.
• To discuss future directions in managing this condition.
• To evaluate the potential role of different revascularization modalities.

Main Methods:

• Review of existing clinical trial data, including STICH and REVIVED-BCIS2.
• Analysis of contemporary medical therapy advancements.
• Synthesis of current literature on ischemic cardiomyopathy management.

Main Results:

• The STICH trial predates modern medical therapy improvements.
• The REVIVED-BCIS2 trial did not demonstrate improved outcomes with percutaneous coronary intervention over medical therapy.
• Significant questions persist regarding the optimal revascularization approach.

Conclusions:

• Current evidence presents a complex picture of revascularization in ischemic cardiomyopathy.
• Further research is needed to clarify the role and modality of revascularization.
• Optimizing patient selection and revascularization techniques may be key to improving outcomes.